Parameter
| Biomarker | Microsatellite instability (MSI-H) | Full name | Microsatellite Instability-High | Molecular Type | Genomic Signatures |
|---|---|---|---|---|---|
| Molecular Formula | Molecular Weight | Core Functional Dimensions | Diagnosis, treatment prediction | ||
| Disease | Colorectal Cancer (CRC) | Disease Subtypes | / | ||
| Organ | Colorectal | Test Sample / Technology Platform | Tumor tissue/blood (NGS, PCR, IHC) | ||
| Pathobiological Mechanisms | DNA mismatch repair defects lead to microsatellite sequence instability, increased tumor mutation burden, and enhanced immunogenicity | ||||
| Clinical Availability Status | Clinically available (treatment options) : It has been included in CRC practice guidelines and used as a marker for predicting the benefit of immunotherapy | ||||
| Notes and Dynamics | It is the first cross-cancer immunotherapy predictive marker, and FDA approved pan-cancer immunotherapy indications based on MSI-H status | ||||